Gilead
Gilead awaits EU decision on hep C combo treatment
December 8, 2015Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir
The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …
EU approval for Gilead’s HIV combo Genvoya
December 1, 2015Manufacturing and Production, Sales and Marketing European Commission, Genvoya, Gilead, Gilead Sciences, HIV, TDF, World Aids Day, european union, taf
Gilead Sciences has won marketing authorisation from the European Commission (EC) for the once-daily single tablet regimen Genvoya as an …
FDA expands Gilead’s Harvoni indications for Hep C
November 13, 2015Sales and Marketing Gilead, Gilead Sciences, harvoni, ledipasvir-sofosbuvir
Gilead’s Harvoni has been approved by the FDA for expanded use in patients with genotypes 4, 5 and 6 chronic …
NICE to recommend three new treatments for hep C
October 16, 2015Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C
NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …
Gilead’s Truvada prevents HIV infections in high-risk men
September 10, 2015Research and Development Gilead, HIV, PrEP, Truvada, pre-exposure prophylaxis treatment, sexually transmitted infections
UK researchers say Truvada, Gilead’s HIV prevention treatment, should be added to the country’s ‘HIV prevention toolkit’, after a study …
NICE restricts access to new hepatitis C treatments
July 29, 2015Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C
NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …
FDA sued over failure to disclose Sovaldi data
June 30, 2015Sales and Marketing FDA, Gilead, hepatitis C, sofosbuvir, sovaldi
Two groups that campaign for wider access to medicines have filed a lawsuit against the FDA, in a bid to …
China rejects Gilead’s Sovaldi patent
June 24, 2015Research and Development, Sales and Marketing China, Gilead, hep C, sofosbuvir, sovaldi
Manufacturer of the blockbuster hepatitis C treatment Sovaldi Gilead has seen its application for a patent in China rejected following …
NICE wants more answers from Gilead on Zydelig
June 18, 2015Sales and Marketing Gilead, MabThera, NICE, Roche, UK, brett wells, zydelig
The National Institute for Health and Care Excellence has not recommended Gilead’s leukaemia drug Zydelig in draft guidance. But the …
Bayer and Gilead expand in manufacturing
June 2, 2015Manufacturing and Production, Sales and Marketing Bayer, Gilead, brett wells, manufacturing
Both Bayer and Gilead are investing heavily into their manufacturing operations with expansion plans being laid down in Indonesia and …
Gilead buys EpiTherapeutics for $65 million
May 7, 2015Sales and Marketing EpiTherapeutics, Gilead
Gilead is clearly eyeing a future market involving epigenetics as the US firm buys Danish company EpiTherapeutics for $65 million. …
The Pharmafocus debate: Is the price of new hepatitis C treatments fair?
April 27, 2015Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi
YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …
Gilead presents new Sovaldi data
April 23, 2015Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi
Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …
Gilead’s next-generation HIV drug to be FDA assessed
April 8, 2015Research and Development, Sales and Marketing F/TAF, FDA, Gilead, HIV, Tenofovir Alafenamide, emtricitabine
Gilead Sciences has filed its second new drug application for a new combination HIV treatment with the FDA.The California-based company …
$10 generic Solvaldi emerges in Bangladesh
March 10, 2015Manufacturing and Production, Sales and Marketing Gilead, World Trade Organization, hep C, incepta, sofosbuvir, sofosbuvir), sovaldi
A Bangladeshi pharma company is producing an unlicensed generic version of Gilead’s hepatitis C drug Sovaldi for $10 per pill …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
